In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Thanks to 3D printing technology, a bioengineer at the McGill University Health Centre is taking personalized health care to a whole new level. Lung regenerative medicine specialist Darcy Wagner and ...

Many of us have them, few of us really hack on them: well, here we’re talking about large home appliances. [Severin von Wnuck ...

A Firestorm xCell micro 3D printing factory loading onto a C-130 to print Tempest UAV systems at a U.S. Air Force base. Inside a standard shipping container, a "factory-in-a-box" hums to life. It is ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Kathleen Elkins Every time Kathleen publishes a story, you’ll get an alert straight to your ...